Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK fusion |
| Therapy | Crizotinib |
| Indication/Tumor Type | inflammatory myofibroblastic tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK fusion | inflammatory myofibroblastic tumor | sensitive | Crizotinib | FDA approved | Actionable | In a Phase Ib trial (PROFILE 1013) that supported FDA approval, treatment with Xalkori (crizotinib) resulted in an objective response rate of 66.7% (6/9, 1 complete response, 5 partial responses) and stable disease in 33.3% (3/9) of adult patients with advanced ALK-positive inflammatory myofibroblastic tumors, with a median duration of response of 74.1 weeks in (PMID: 29352732; NCT01121588). | 29352732 detail... |
| ALK fusion | inflammatory myofibroblastic tumor | sensitive | Crizotinib | FDA approved | Actionable | In a Phase I/II trial (Study ADVL0912) that supported FDA approval, Xalkori (crizotinib) therapy was safe and resulted in an objective response rate of 86% (12/14, 5 complete responses, 7 partial responses) and stable disease in 14% (2/14) of pediatric patients with ALK-positive unresectable inflammatory myofibroblastic tumors, with a median duration of response of 1.63 years (PMID: 28787259; NCT00939770). | detail... 28787259 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28787259) | Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. | Full reference... |
| Xalkori (crizotinib) FDA Drug Label | Full reference... | |
| Xalkori (crizotinib) FDA Drug Label | Full reference... | |
| (29352732) | Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. | Full reference... |